Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Breast cancer is the most commonly diagnosed malignancy among women worldwide. With continued advances in systemic treatment and surgical techniques, patient survival has improved significantly, making postoperative quality of life and the restoration of physical and psychological well-being increasingly important components of comprehensive breast cancer care. Breast reconstruction is not only a concentrated expression of surgical expertise but also an important means of helping patients return to normal life, making it an integral part of breast cancer prevention and treatment.
ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer has become a major focus of research in recent years. A central unresolved question has been whether improvements in pathological complete response (pCR) rates can translate into meaningful survival benefits. At the same time, developing individualized neoadjuvant strategies for patients with different molecular subtypes based on biomarkers remains an urgent clinical priority.
Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

At the 2026 European Society for Medical Oncology (ESMO) Congress, the Department of Urology at West China Hospital of Sichuan University reported interim results from the WUTSUP-02 study, which explored the value of neoadjuvant treatment with disitamab vedotin plus tislelizumab, followed by surgery and adjuvant tislelizumab, in patients with high-risk upper tract urothelial carcinoma (UTUC). Addressing the limited perioperative treatment options for this patient population, Professor Yige Bao of West China Hospital of Sichuan University discusses the rationale behind the WUTSUP-02 study, its interim efficacy findings, and future directions for patient selection and evidence generation.
ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

RET fusions are rare oncogenic driver alterations in NSCLC. As the first RET inhibitor approved in China, pralsetinib has the ARROW study as a key foundation of its clinical evidence. A post hoc reanalysis presented at ESMO 2026 showed that first-line pralsetinib provides significant benefits in tumor shrinkage and disease control, while also improving tumor-related symptoms and supporting both efficacy and quality of life. Oncology Frontier invited Professor Yilong Wu from Guangdong Provincial People's Hospital to interpret the findings. He emphasized that results from single-arm studies should not be directly compared across trials and that baseline imbalances must be taken into account. These findings provide important evidence supporting first-line treatment of advanced RET fusion-positive NSCLC.
ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

In the treatment of head and neck cancers, particularly oral squamous cell carcinoma (OSCC), clinicians have long faced a difficult trade-off: achieving radical tumor control often requires surgery that sacrifices critical anatomical structures, including the tongue, floor of the mouth, and jawbone, all of which are essential for speech, swallowing, and appearance. To further reduce the risk of local recurrence, postoperative radiotherapy or concurrent chemoradiotherapy is frequently added. However, the resulting complications, such as trismus, xerostomia, dysphagia, and tissue fibrosis, can continue to impair patients' quality of life for years.
ESMO 2026 | Interim Results from a Neoadjuvant Study in Locally Advanced Cervical Cancer: QL1706 Plus Chemotherapy, with 14 Patients Undergoing Surgery

ESMO 2026 | Interim Results from a Neoadjuvant Study in Locally Advanced Cervical Cancer: QL1706 Plus Chemotherapy, with 14 Patients Undergoing Surgery

Concurrent chemoradiotherapy remains the standard treatment for locally advanced cervical cancer. For high-risk patients with a substantial tumor burden, extensive local invasion, or lymph node metastases, rapidly reducing tumor burden early in treatment and creating favorable conditions for subsequent definitive therapy remain important clinical challenges.
2026 IFSC | Professor Michael Milsom on Inflammation-Driven Hematopoietic Aging and Clonal Hematopoiesis: From Mechanisms to Opportunities for Intervention

2026 IFSC | Professor Michael Milsom on Inflammation-Driven Hematopoietic Aging and Clonal Hematopoiesis: From Mechanisms to Opportunities for Intervention

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontier areas in global hematology and regenerative medicine. Centered on these topics, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational research on hematopoietic stem cells, and promote collaborative innovation in the global stem cell field.